|  | LH | Androstenedione | ||||
---|---|---|---|---|---|---|---|
 |  | Preoperative | Postoperative | P | Preoperative | Postoperative | P |
Total study population |  | 15.1 ± 6.0 | 6.4 ± 4.0 | < 0.001 | 3.2 ± 0.9 | 2.2 ± 1.6 | < 0.001 |
LH | ≤12.1 IU/l | 8.4 ± 2.2 | 6.1 ± 3.3 | 0.004 | 3.1 ± 1.0 | 3.0 ± 2.7 | 0.708 |
 | >12.1 IU/l | 18.0 ± 4.6 | 6.6 ± 4.3 | < 0.001 | 3.2 ± 0.9 | 1.9 ± 0.7 | < 0.001 |
Androstenedione | ≤3.26 mg/dl | 14.5 ± 5.4 | 6.5 ± 4.3 | < 0.001 | 2.6 ± 0.5 | 1.8 ± 0.6 | < 0.001 |
 | >3.26 mg/dl | 16.0 ± 6.7 | 6.4 ± 3.5 | < 0.001 | 6.4 ± 0.9 | 2.7 ± 2.3 | < 0.001 |
LH and androstenedione | LH ≤ 12.1 IU/l or androstenedione ≤ 3.26 mg/dl | 13,7 ± 5,4 | 6,6 ± 4,0 | < 0.001 | 2.8 ± 0.8 | 2.3 ± 2.0 | 0.029 |
 | LH >12.1 IU/l and androstenedione >3.26 mg/dl | 18,3 ± 5,9 | 6,1 ± 4,0 | < 0.001 | 3.9 ± 0.8 | 2.0 ± 0.6 | < 0.001 |